Single-step antigen loading and TLR activation of dendritic cells by mRNA electroporation for vaccination in stage III and IV melanoma patients.
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2012
At a glance
- Drugs TriMix DC (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 09 Feb 2012 Additional primary endpoints identified and added as reported by ClinicalTrials.gov.
- 09 Feb 2012 Planned number of patients changed from 34 to 35 as reported by ClinicalTrials.gov.
- 09 Feb 2012 Planned end date changed from 1 Feb 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.